Hyperlipidemia NCEP recommendations for drug therapy of high-risk hyperlipidemia in children and adolescents: Difference between revisions
Jump to navigation
Jump to search
m (Robot: Automated text replacement (-{{WikiDoc Cardiology Network Infobox}} +, -<references /> +{{reflist|2}}, -{{reflist}} +{{reflist|2}})) |
Hardik Patel (talk | contribs) No edit summary |
||
Line 1: | Line 1: | ||
__NOTOC__ | |||
{{CMG}} | {{CMG}} | ||
Line 13: | Line 14: | ||
==Overview== | ==Overview== | ||
Children and adolescents with high-risk hyperlipidemia require lipid-lowering drug therapy, particularly those with familial hypercholesterolemia, despite compliance with lifestyle recommendations. | Children and adolescents with high-risk hyperlipidemia require lipid-lowering drug therapy, particularly those with familial hypercholesterolemia, despite compliance with lifestyle recommendations. | ||
==NCEP | ==NCEP Recommendations for Drug Therapy of High-Risk Hyperlipidemia in Children and Adolescents== | ||
===Original Recommendations of the National Cholesterol Education Program (NCEP) Expert Panel for Drug Therapy of High-Risk Hyperlipidemia in Children and Adolescents <ref name="pmid17377073">{{cite journal| author=McCrindle BW, Urbina EM, Dennison BA, Jacobson MS, Steinberger J, Rocchini AP et al.| title=Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. | journal=Circulation | year= 2007 | volume= 115 | issue= 14 | pages= 1948-67 | pmid=17377073 | doi=10.1161/CIRCULATIONAHA.107.181946 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17377073 }} </ref> ( | ===Original Recommendations of the National Cholesterol Education Program (NCEP) Expert Panel for Drug Therapy of High-Risk Hyperlipidemia in Children and Adolescents <ref name="pmid17377073">{{cite journal| author=McCrindle BW, Urbina EM, Dennison BA, Jacobson MS, Steinberger J, Rocchini AP et al.| title=Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. | journal=Circulation | year= 2007 | volume= 115 | issue= 14 | pages= 1948-67 | pmid=17377073 | doi=10.1161/CIRCULATIONAHA.107.181946 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17377073 }} </ref> (DO NOT EDIT)=== | ||
{{cquote| | {{cquote| | ||
Line 33: | Line 33: | ||
}} | }} | ||
===Current | ===Current Modification of the National Cholesterol Education Program (NCEP) Expert Panel for Drug Therapy of High-Risk Hyperlipidemia in Children and Adolescents <ref name="pmid17377073">{{cite journal| author=McCrindle BW, Urbina EM, Dennison BA, Jacobson MS, Steinberger J, Rocchini AP et al.| title=Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. | journal=Circulation | year= 2007 | volume= 115 | issue= 14 | pages= 1948-67 | pmid=17377073 | doi=10.1161/CIRCULATIONAHA.107.181946 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17377073 }} </ref> (DO NOT EDIT)=== | ||
{{cquote| | {{cquote| |
Revision as of 12:42, 25 October 2012
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
For patient information click here
Template:DiseaseDisorder infobox
WikiDoc Resources for Hyperlipidemia NCEP recommendations for drug therapy of high-risk hyperlipidemia in children and adolescents |
Articles |
---|
Media |
Evidence Based Medicine |
Clinical Trials |
|
Guidelines / Policies / Govt |
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
|
Healthcare Provider Resources |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Overview
Children and adolescents with high-risk hyperlipidemia require lipid-lowering drug therapy, particularly those with familial hypercholesterolemia, despite compliance with lifestyle recommendations.
NCEP Recommendations for Drug Therapy of High-Risk Hyperlipidemia in Children and Adolescents
Original Recommendations of the National Cholesterol Education Program (NCEP) Expert Panel for Drug Therapy of High-Risk Hyperlipidemia in Children and Adolescents [1] (DO NOT EDIT)
“ |
|
” |
Current Modification of the National Cholesterol Education Program (NCEP) Expert Panel for Drug Therapy of High-Risk Hyperlipidemia in Children and Adolescents [1] (DO NOT EDIT)
“ |
|
” |
References
- ↑ 1.0 1.1 McCrindle BW, Urbina EM, Dennison BA, Jacobson MS, Steinberger J, Rocchini AP; et al. (2007). "Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing". Circulation. 115 (14): 1948–67. doi:10.1161/CIRCULATIONAHA.107.181946. PMID 17377073.